Allergy Drug May Reduce Relapse in Neuromyelitis Optica
Friday, February 23, 2018 | Medical Studies
The popular allergy medication cetirizine (Zyrtec, Johnson & Johnson Consumer Inc), when added to standard therapy, shows the potential to reduce the rate of relapse of the neuromyelitis optica (NMO), in a small but important study.
"We were pleased to find that cetirizine was safe and well-tolerated in our population of NMO patients," senior author, Illana Katz Sand, MD, assistant professor of neurology at the Icahn School of Medicine at Mount Sinai, New York City, said in a press statement.
"While the study's open-label design and small sample size preclude definitive conclusions, we did detect a signal that suggested cetirizine may be of benefit."
You must be logged in to leave a comment.